| Previous Close | 0.0340 |
| Open | 0.0340 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0335 - 0.0450 |
| 52 Week Range | 0.0200 - 0.2200 |
| Volume | 3,100 |
| Avg. Volume | 24,609 |
| Market Cap | 489,127 |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2430 |
| Earnings Date | Jun 29, 2020 - Jun 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / November 14, 2019 / Adhera Therapeutics, Inc. (ATRX), an emerging specialty pharmaceutical company that commercializes and delivers effective, patient-centric treatment in chronic care, to improve and simplify the quality of care for patients suffering from chronic diseases, reported financial and operating results for the third quarter of 2019 today. During the third quarter the Company achieved three important milestones in progressing its ‘invest to grow' strategy and removing barriers to performance, by scaling up 1) its marketing capabilities, 2) its distribution capabilities and 3) its product portfolio. Marketing - The Company entered into a strategic partnership with Indegene Inc. to deploy Indegene's proprietary co-commercialization model to expand commercialization for the Company's primary product, Prestalia®, across the United States.
Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced offer to exchange all of the outstanding shares of the Series E Convertible Preferred Stock and Series F Convertible Preferred Stock of the Company. As per the terms of the offer, the Company offered, in exchange for each share of preferred stock tendered, such number of shares of the common stock of the Company as is equal to the quotient obtained by dividing (A) the “stated value” of such tendered share of preferred stock by (B) $0.50 (subject to an adjustment mechanism described in the Schedule TO).
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into a partnership with Indegene Inc. to deploy the proprietary Indegene co-commercialization model to expand commercialization for its drug, PRESTALIA®, across the United States. PRESTALIA® (https://PRESTALIA-us.net/package-insert) combines two key hypertensive agents, perindopril arginine and amlodipine besylate, and is indicated for the treatment of hypertension.
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 6, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into an agreement with Allegis Pharmaceuticals, LLC to co-promote Allegis’ Nitrolingual® Pumpspray, a nitroglycerin lingual spray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin is listed as one of the top 300 most prescribed drugs with approximately 3.4 million annual prescriptions in 2016 (https://clincalc.com/DrugStats/Top300Drugs.aspx).
Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced offer to exchange all of the warrants to purchase shares of the common stock of the Company that the Company issued in connection with its private placements of Series E Convertible Preferred Stock and Series F Convertible Preferred Stock during 2018. As per the terms of the offer, the Company offered two shares of its common stock in exchange for each warrant tendered.